Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates

Madrigal posts $431.3M Q3 revenue and $55.4M profit, driven by Rezdiffra sales.

What the company is saying

Madrigal Pharmaceuticals highlights a transformative quarter, emphasizing that Rezdiffra has surpassed $1 billion in year-to-date net sales, achieving blockbuster status in under three years. The company frames its narrative around strong demand, deepening prescriber adoption, and rapid market growth, positioning itself as a leader in the MASH therapeutic space. Management claims the addressable U.S. F2-F3 market will grow over 30% by year-end 2026, and spotlights the upcoming MAESTRO-CSPH Phase 3 trial as a key strategic move, aiming to extend its competitive advantage. The company also underscores its scientific leadership, noting that Rezdiffra will be featured in more abstracts than any other MASH therapy at the AASLD Liver Meeting, including real-world evidence from nearly 12,000 patients. A secondary analysis of the MAESTRO-NASH trial is cited to support Rezdiffra’s efficacy across key genetic risk variants. The appointment of Dr. John C. Reed, a senior executive at Johnson & Johnson, to the board is presented as a further credibility boost. Explanations for financial changes are explicit: revenue growth is attributed to U.S. Rezdiffra demand, higher cost of sales to increased Roche royalties, lower R&D to the absence of a prior-year $117.3 million one-time business development expense, and higher SG&A to commercial expansion and marketing.

What the data suggests

The numbers confirm a sharp financial turnaround: Q3 2026 net revenues rose 50% year-over-year to $431.3 million, with net income of $55.4 million ($1.90 per basic share, $1.83 per diluted share), reversing a $114.2 million loss in the prior year. Year-to-date net product revenue reached $1.1 billion, up from $637.3 million, confirming blockbuster status for Rezdiffra. Operating expenses for Q3 were $375.3 million, down from $401.2 million, with $38.9 million in non-cash stock-based compensation. Cost of sales doubled to $37.8 million, mainly due to higher Roche royalties. R&D expenses dropped to $71.8 million from $174.0 million, reflecting the absence of a $117.3 million one-time expense last year. SG&A rose to $265.7 million, driven by commercial expansion and a direct-to-consumer campaign. Cash and equivalents stood at $961.8 million at quarter-end, down slightly from $988.6 million at year-end 2025. The company’s balance sheet remains strong, with total assets of $1.43 billion and equity of $626.9 million. While scientific and market growth claims are not backed by new quantitative data, the financial disclosures are detailed and transparent, supporting the narrative of rapid commercial growth.

Analysis

The announcement is generally positive and well-supported by realised financial results: Rezdiffra has surpassed $1 billion in year-to-date net sales, and the company has transitioned from a net loss to net income in the latest quarter. These are concrete, measurable achievements, and the release provides detailed revenue, profit, and expense figures, satisfying the disclosure completeness rule. Some forward-looking statements—such as the projected 30% increase in the addressable market and the planned MAESTRO-CSPH Phase 3 trial—are aspirational and lack supporting data or regulatory confirmation, but they are not the majority of the claims. The tone is optimistic but not excessively promotional, with most language proportionate to the evidence. There is no indication of a large capital outlay paired with only long-dated, uncertain returns; commercial investments are ongoing but justified by realised sales growth. The main gap is the lack of quantitative detail for certain scientific and market projections.

Risk flags

• ●Future growth is partly predicated on the projected 30% expansion of the addressable U.S. F2-F3 market by year-end 2026, but no third-party data or detailed methodology is provided to substantiate this forecast, introducing market sizing risk.
• ●The MAESTRO-CSPH Phase 3 trial, a key pipeline driver, is scheduled to initiate in the first half of 2027 and is still subject to regulatory discussions, creating execution risk around trial timing, enrollment, and potential regulatory delays.
• ●Cost structure remains high, with Q3 2026 operating expenses at $375.3 million and SG&A rising due to commercial expansion and marketing; if Rezdiffra sales growth slows or market expansion underperforms, profitability could be pressured.
• ●Scientific claims regarding Rezdiffra’s efficacy across genetic variants and the breadth of real-world evidence are asserted without detailed quantitative results or peer-reviewed data in this release, limiting independent validation of clinical differentiation.
• ●While the appointment of Dr. John C. Reed adds board-level expertise, his presence does not guarantee future clinical or commercial success, and reliance on high-profile individuals can create key-person risk if expectations are not met.

Bottom line

Madrigal’s Q3 2026 results mark a decisive shift to profitability, with $431.3 million in revenue and $55.4 million in net income, driven by surging Rezdiffra sales. The company’s financial disclosures are robust, supporting claims of strong commercial momentum and a solid balance sheet with $961.8 million in cash and equivalents. Forward-looking growth depends on both continued Rezdiffra adoption and successful execution of the MAESTRO-CSPH Phase 3 trial, which will not begin until 2027 and remains contingent on regulatory progress. Market expansion and scientific leadership are asserted but not quantitatively substantiated in this release, leaving some claims aspirational. Investors should focus on monitoring Rezdiffra’s sales trajectory, cost discipline, and concrete milestones for the next clinical trial. The most important takeaway is that Madrigal has delivered a profitable quarter and blockbuster product revenue, but future upside relies on execution in both commercial and late-stage clinical arenas.

Announcement summary

(NASDAQ:MDGL) Madrigal Pharmaceuticals, Inc. reported third-quarter 2026 financial results and provided corporate updates. Bill Sibold, Chief Executive Officer, stated that Rezdiffra surpassed $1 billion in year-to-date net sales, achieving blockbuster status less than three years after launch. The company’s analysis indicates the addressable U.S. F2-F3 market is on track to increase more than 30 percent by year-end 2026. Madrigal plans to initiate the MAESTRO-CSPH Phase 3 outcomes trial in the first half of 2027, enrolling more than 2,000 F4c patients, with a focus on clinically significant portal hypertension (CSPH). The trial is designed to generate the broadest dataset in F4c and support validation of noninvasive biomarkers for Rezdiffra and future pipeline programs. Madrigal will have a significant presence at the AASLD Liver Meeting from Nov. 5-9, 2026, with eighteen abstracts accepted, including thirteen based on real-world evidence, and the largest data set spanning nearly 12,000 patients. A secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression, including PNPLA3, HSD17B13, TM6SF2, MTARC1, and MBOAT7. In August 2026, Dr. John C. Reed was appointed to Madrigal’s Board of Directors; he is currently Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson. Third-quarter 2026 net revenues were $431.3 million, up 50% from $287.3 million in the prior year period, driven by increased demand for Rezdiffra in the U.S. Operating expenses for the quarter were $375.3 million, including $38.9 million in non-cash stock-based compensation, compared to $401.2 million, including $26.3 million in non-cash stock-based compensation, in the prior year period. Cost of sales was $37.8 million compared to $18.1 million in the prior year period, primarily due to higher royalties payable to Roche. R&D expenses were $71.8 million compared to $174.0 million in the prior year period, both inclusive of non-cash stock-based compensation, with the decrease primarily due to a one-time, upfront business development expense of $117.3 million in the prior year. SG&A expenses were $265.7 million compared to $209.1 million in the prior year period, both inclusive of non-cash stock-based compensation, with the increase due to continued investment in commercial activities for Rezdiffra, including endocrinology field force expansion and a direct-to-consumer campaign. Third-quarter 2026 net income was $55.4 million, or $1.90 per basic share and $1.83 per diluted share, compared to a net loss of $114.2 million, or $4.01 per basic and diluted share, in the prior year period. As of September 30, 2026, Madrigal had cash, cash equivalents, restricted cash, and marketable securities of $961.8 million compared to $988.6 million as of December 31, 2025. For the nine months ended September 30, 2026, product revenue, net was $1,106,857,000 compared to $637,320,000 in the prior year period. Total operating expenses for the nine months ended September 30, 2026, were $1,199,899,000 compared to $877,808,000 in the prior year period. Net loss for the nine months ended September 30, 2026, was $96,888,000 compared to $229,709,000 in the prior year period. As of September 30, 2026, total assets were $1,434,389,000 and total liabilities and stockholders’ equity were $1,434,389,000. Current liabilities as of September 30, 2026, were $454,244,000 and long-term liabilities were $353,204,000. Stockholders’ equity as of September 30, 2026, was $626,941,000. Madrigal will host a webcast at 8 a.m. EST on November 3, 2026, to review its financial and operating results and provide a business update.

Disagree with this article?